Nitin Naik, Frost & Sullivan

Nitin Naik Nitin has close to 20 years of healthcare industry knowledge, including 10 plus years of consulting expertise focusing on the pharmaceutical and biotechnology sector. His industry expertise covers key healthcare sectors from pharmaceuticals and biotechnology to clinical diagnostics and clinical research. Expertise in Translational R&D (Biologics & Small molecules), Oncology (Brain Tumors; Breast & Prostate Cancer), Antimicrobials (Nanopolymers, Peptides and Quorum Sensing compounds), In-vitro Toxicology. Nitin has detailed industry and therapeutic area expertise, including knowledge of key emerging and established markets from a market, regulatory and reimbursement point of view.  He has an in-depth understanding of healthcare markets across the world from government healthcare structures and policy to end user and market evaluations. Prior to his current position, Nitin spent 5-10 years each with GE Healthcare (national distributor), Frost & Sullivan Asia & A*STAR Singapore in various roles from strategy, marketing to in-licensing, portfolio management and market planning.  He has facilitated several regional and global strategic alliances.  At Frost & Sullivan Asia, he established a responsive, multi-million-dollar consulting business unit and he tripled revenues for Japan business in 2 years. At A*STAR, he championed business transformation initiatives to strengthen Singapore’s position # 1: Pharma Drug Development (D3) # 2: Diagnostics (DxD) Hub # 3: A*START Central #4: Biopharma Manufacturing Hub.  Received Excellence Award from Taiwan’s National Biotech agency to design the 5-year blue print for the local industry. Education: Advanced Management Program (Corporate Strategy & Finance) from Stanford-NUS, MBA (International Business-SPJIMR) and a Bachelor’s degree in Biomedical Engineering (Gold Medalist) from Bombay University.


1:30 PM - 2:00 PM

Realizing the Potential of Virtual and Hybrid Clinical Trials

The need to increase the speed of patient recruitment, improve retention, and enhance data quality – all while lowering costs, has led to the current interest in virtual and hybrid clinical trials. The question is, how do you know when a virtual or hybrid study makes sense? This session will focus on the critical differences between traditional and virtual or hybrid trials that need to be considered.

  • What therapeutic areas are most effective using virtual and hybrid trials?
  • The importance of protocol design and a distribution and tracking plan for medication.
  • What steps need to be taken to ensure the safety of patients?
  • If the home is the new trial site, how is that different? What do you need to do differently from the start of the process through the end of the trial?
  • Understanding How Digital Therapeutics Will Change the Clinical Trial Paradigm.


  • Nitin Naik

    Nitin Naik Vice President-Global Life Sciences, Transformational Health Frost & Sullivan


  • Mohammed Ali

    Mohammed Ali Global Head Digital Trials- Global Clinical Operations Boehringer Ingelheim Pharmaceuticals, Inc.

Download Latest Agenda